Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 4Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Pleural Effusion, Malignant 1Neoplasms, Plasma Cell 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 39Cisplatin 24Oxaliplatin 15pembrolizumab 12Capecitabine 12Fluorouracil 9Leucovorin 7Albumin-Bound Paclitaxel 7lenvatinib 6Radiofrequency Ablation 6Panitumumab 6130-nm albumin-bound paclitaxel 6Irinotecan 5Bevacizumab 5durvalumab 4Taxes 4Nivolumab 4Hepatectomy 4Drug Therapy 4tremelimumab 3apatinib 3Radiosurgery 3Platinum 3Injections 3Floxuridine 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3trametinib 2spartalizumab 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cholangiocarcinoma × saracatinib × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡